• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Financial Services·SFE
Share

Safeguard Scientifics, Inc. Stocks

$ 0Last Updated 23.03.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

$ 7.54M

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Safeguard Scientifics, Inc., a former private equity and venture capital firm, is no longer actively seeking new investments. Historically, the firm specialized in a broad range of financing activities, including providing capital for company expansion and growth, facilitating management buyouts, executing recapitalizations, driving industry consolidations, and supporting corporate spin-offs. Their investment scope covered both early and growth-stage companies. Typically, Safeguard Scientifics participated in Series A, B, or C funding rounds, with an opportunistic approach to seed-stage investments. Their primary sector focus spanned technology, financial services, and healthcare. Within the technology sphere, their interests were diverse, encompassing areas such as software-as-a-service (SaaS), adtech, digital media, the Internet of Everything (IoE), advanced security solutions, predictive analytics, machine learning, artificial intelligence, enterprise software, technology-enabled services, internet/new media, financial technology (FinTech), cloud computing, mobile, social platforms, big data, in-memory computing, and select business services. For these tech ventures, they considered companies requiring up to $25 million in capital. In the healthcare sector, the firm directed its investments towards molecular and point-of-care diagnostics, various medical devices, regenerative medicine, broader medical technology, digital health solutions, healthcare technology, specialized pharmaceuticals, and chosen healthcare services. Geographically, Safeguard Scientifics invested across the entire United States, with a particular emphasis on the Mid-Atlantic region, and also extended its reach into Southeastern Canada. Financial commitments for growth equity financing generally ranged from $5 million to $25 million, while early-stage financings typically saw investments between $5 million and $10 million. The firm's investment strategy often targeted a variety of capital structures, including self-funded (bootstrapped) companies, corporate divisions or business units, and venture capital-backed entities seeking a growth partner. Safeguard Scientifics aimed to be the largest stakeholder in its portfolio companies, typically acquiring an ownership stake between 20% and 50%, though they were flexible and might occasionally take either a majority or a smaller interest. A strong preference existed for companies possessing proprietary technology and intellectual property. Furthermore, the firm routinely sought a Board seat in its invested companies. Founded in 1953 as Lancaster Corporation, the company adopted the name Safeguard Scientifics, Inc. in 1981. Its main office is located in Radnor, Pennsylvania, with an additional presence in Weston, Massachusetts.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

04.08.2026 09:00

Trump criticized ExxonMobil and Chevron over their record profits and gas prices

04.08.2026 08:00

The last "bear" rejected the advice to sell Boeing stock. What changed his mind?

04.08.2026 03:41

Palantir reported "superb" results and raised its forecasts

04.08.2026 02:10

U.S. stocks had their best start to the month in four years. The Dow hit a new record high.

04.08.2026 01:35

Tankers have resumed loading oil from Kazakhstan at a key terminal following the attacks

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026